BEAT-Lupus clinical trial shows promise of new treatment for lupus
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet Rheumatology
BEAT-Lupus clinical trial shows promise of new treatment for lupus
Treatment of lupus nephritis: consensus, evidence and perspectives | Nature Reviews Rheumatology
Promising experimental treatments for lupus nephritis | RRU
JCM | Free Full-Text | Targeted Therapy for SLE—What Works, What Doesn’t, What’s Next
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet Rheumatology
Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial | Trials | Full Text
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet Rheumatology
PDF) Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial
Lupus landmark trials | PPT
New therapies for systemic lupus erythematosus — past imperfect, future tense | Nature Reviews Rheumatology
PDF) Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
PDF) Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol | BMJ Open
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan | Trials | Full Text
OP0129 BELIMUMAB AFTER RITUXIMAB SIGNIFICANTLY REDUCED IGG ANTI-DSDNA ANTIBODY LEVELS AND PROLONGED TIME TO SEVERE FLARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Annals of the Rheumatic Diseases
Voclosporin for Lupus Nephritis — NephJC
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation | Nature Reviews Rheumatology
RT @uptoTate: BEAT LUPUS trial results showed that belimumab after RTX reduced dsDNA levels/flaring. Questions remain if | RheumNow
Laurent ARNAUD on X: "Let's review the design of BLISS-BELIEVE, the phase 3 trial based on the #rituximab + #belimumab combination in systemic #Lupus. The primary endpoint is very ambitious but very
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial - UCL Discovery
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. | Semantic Scholar
Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments | Lupus Science & Medicine
